These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 31756301)

  • 21. Initial treatment of CLL: integrating biology and functional status.
    Jain N; O'Brien S
    Blood; 2015 Jul; 126(4):463-70. PubMed ID: 26065656
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness of first-line vs third-line ibrutinib in patients with untreated chronic lymphocytic leukemia.
    Patel KK; Isufi I; Kothari S; Davidoff AJ; Gross CP; Huntington SF
    Blood; 2020 Oct; 136(17):1946-1955. PubMed ID: 32518952
    [TBL] [Abstract][Full Text] [Related]  

  • 23. SOHO State of the Art Updates and Next Questions: BTK inhibitors combined with chemoimmunotherapy in CLL, the best of both worlds?
    Thompson PA
    Clin Lymphoma Myeloma Leuk; 2022 Apr; 22(4):205-209. PubMed ID: 34774461
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel Therapies in Chronic Lymphocytic Leukemia: A Rapidly Changing Landscape.
    Iovino L; Shadman M
    Curr Treat Options Oncol; 2020 Mar; 21(4):24. PubMed ID: 32170458
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Relapsed CLL: sequencing, combinations, and novel agents.
    Brown JR
    Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):248-255. PubMed ID: 30504318
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Real-world Prescription Pattern, Discontinuation and Costs of Ibrutinib-Naïve Patients with Chronic Lymphocytic Leukemia: An Italian Healthcare Administrative Database Analysis.
    Ronconi G; Dondi L; Calabria S; Piccinni C; Pedrini A; Esposito I; Martini N
    Clin Drug Investig; 2021 Jul; 41(7):595-604. PubMed ID: 34032988
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Keeping a balance in chronic lymphocytic leukemia (CLL) patients taking ibrutinib: ibrutinib-associated adverse events and their management based on drug interactions.
    Cho HJ; Baek DW; Kim J; Lee JM; Moon JH; Sohn SK
    Expert Rev Hematol; 2021 Sep; 14(9):819-830. PubMed ID: 34375536
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Frontline Treatment of the Young, Fit Patient with CLL: A Canadian Perspective.
    Costello J; Kang M; Banerji V
    Curr Oncol; 2021 Sep; 28(5):3825-3835. PubMed ID: 34677244
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic markers and standard management of chronic lymphocytic leukemia.
    Stilgenbauer S
    Hematology Am Soc Hematol Educ Program; 2015; 2015():368-77. PubMed ID: 26637745
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The clinical safety of ibrutinib in chronic lymphocytic leukemia.
    Molica S
    Expert Opin Drug Saf; 2015 Oct; 14(10):1621-9. PubMed ID: 26359217
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Current Treatment of Chronic Lymphocytic Leukemia.
    Jamroziak K; Puła B; Walewski J
    Curr Treat Options Oncol; 2017 Jan; 18(1):5. PubMed ID: 28185174
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Progress in the treatment of elderly/unfit chronic lymphocytic leukemia patients: results of the German CLL-11 trial.
    Molica S
    Expert Rev Anticancer Ther; 2015 Jan; 15(1):9-15. PubMed ID: 25479582
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia in older adults without deletion 17p.
    Barnes JI; Divi V; Begaye A; Wong R; Coutre S; Owens DK; Goldhaber-Fiebert JD
    Blood Adv; 2018 Aug; 2(15):1946-1956. PubMed ID: 30097461
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Frontline Therapy of Chronic Lymphocytic Leukemia: Changing Treatment Paradigm.
    Sengar M; Jain H; Rajendra A; Rengaraj K; Thorat J
    Curr Hematol Malig Rep; 2020 Jun; 15(3):168-176. PubMed ID: 32542586
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Chronic lymphocytic leukemia: pathophysiology and current therapy].
    Takizawa J
    Rinsho Ketsueki; 2017; 58(5):471-479. PubMed ID: 28592762
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Chronic lymphocytic leukemia: update on pathophysiology and management].
    Suzumiya J
    Rinsho Ketsueki; 2018; 59(5):511-520. PubMed ID: 29877241
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Management of unfit elderly patients with chronic lymphocytic leukemia.
    Eichhorst B; Hallek M; Goede V
    Eur J Intern Med; 2018 Dec; 58():7-13. PubMed ID: 30527922
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The impact of increasing karyotypic complexity and evolution on survival in patients with CLL treated with ibrutinib.
    Kittai AS; Miller C; Goldstein D; Huang Y; Abruzzo LV; Beckwith K; Bhat SA; Bond DA; Grever MR; Heerema NA; Rogers KA; Ruppert AS; Byrd JC; Woyach JA
    Blood; 2021 Dec; 138(23):2372-2382. PubMed ID: 34314481
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel Therapies for Chronic Lymphocytic Leukemia: A Canadian Perspective.
    Owen C; Assouline S; Kuruvilla J; Uchida C; Bellingham C; Sehn L
    Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):627-634.e5. PubMed ID: 26416145
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Destabilization of ROR1 enhances activity of Ibrutinib against chronic lymphocytic leukemia in vivo.
    Liu Z; Liu J; Zhang T; Shi M; Chen X; Chen Y; Yu J
    Pharmacol Res; 2020 Jan; 151():104512. PubMed ID: 31726100
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.